Lung Cancer Drug Development: Prolonging Life v. Treating Symptoms
FDA’s next patient-focused drug development meeting will ask what’s most important when diagnosed with a disease that has a median survival time of a little over a year.
FDA’s next patient-focused drug development meeting will ask what’s most important when diagnosed with a disease that has a median survival time of a little over a year.